Ramji Rajendran, Radiation Oncologist at UroPartners LLC, shared on LinkedIn:
“EXTEND Trial: Adding oligo-metastasis directed SBRT to SOC systemic therapy 350 pts randomized +/- SBRT.
53 months median follow up: PFS improved.
This was seen in prostate cancer, pancreatic cancer, and other baskets.
Breast and kidney cancers remain inconclusive.
Interestingly, ctDNA clearance at 3 months correlates with improved survival.
Systemic immune reactions from SBRT + SOC systemic therapy also had PFS superiority.
This phase II study supports histology specific efficacy signals for phase III studies.”
Title: Addition of Metastasis-Directed Therapy to Standard of Care for Oligometastatic Disease: Primary Aggregated Analysis of All Baskets from the Phase II Randomized EXTEND Trial
Authors: Alexander D. Sherry, Cara Haymaker, Shuqi Wang, Suyu Liu, Tharakeswara K. Bathala, Marina N. Medina-Rosales, Aaron Seo, Kieko Hara, Jay Reddy, Stephen G. Chun, Lauren L. Mayo, Gary Walker, Shubham Pant, Dan Zhao, Craig A. Kovitz, David Ramirez, Chul S. Ha, Benjamin D. Smith, Daniel Gomez, Lorenzo Cohen, Albert C. Koong, Alexandre Reuben, Nizar Tannir, Paul G. Corn, Phuoc T. Tran, Bilal A. Siddiqui, Sumit K. Subudhi, Pavlos Msaouel, Ethan B. Ludmir, Chad Tang
Other articles about oligometastatic cancer on OncoDaily.